At EBMT 2025, Professor Sebastian Giebel shared key data from a real-world, multicenter study on CART19 therapy in 345 B-ALL patients. The study highlights how prior alloHCT exposure impacts survival and relapse outcomes.
While CART19 remains effective, early relapse post-alloHCT (<6 months) significantly worsened 2-year OS (43%) and LFS (30%), compared to those relapsing later. In alloHCT-naïve patients, active disease and resistance to blinatumomab or inotuzumab were the strongest predictors of poor outcomes.
This study reinforces the need to tailor CART19 use based on prior therapies and disease burden.
Thanks to Prof. Sebastian Giebel for sharing these important insights.
For more details: https://lnkd.in/gKBDhBKz
